Nick Marsh

Nick Marsh has over 20 years of work experience in the field of molecular pharmacology. Nick began their career at Aegera Therapeutics Inc. in 1998 as a Senior Scientist. In 2001, they joined Archemix Corp. and held various roles, including Director of In Vitro Pharmacology, Associate Director of In Vitro Pharmacology, Senior Principal Investigator, and Senior Scientist. In 2007, they moved to Bristol Myers Squibb where they served as Group Director of Biomolecular Characterization, Senior Director of Preclinical Discovery & Development, and Director of Pharmacology and Preclinical Assays. In 2013, they were invited to join Harvard University as Faculty in Translational Pharmacology BCMP 301QC. In 2019, they became a Member of the Board of Trustees at Cambridge Friends School. Most recently, they are the Head of Molecular Pharmacology at Arrakis Therapeutics.

Nick Marsh earned their Doctor of Philosophy (Ph.D.) in Pharmacology from the University of Chicago. Nick then completed a Post Doc at McGill University's Brain Tumor Research Center from 1995 to 1998. Nick received their B.A. in Biology from Lawrence University.